Intrinsic value of MiMedx Group - MDXG

Previous Close

$13.83

  Intrinsic Value

$8.13

stock screener

  Rating & Target

sell

-41%

  Value-price divergence*

-150%

Previous close

$13.83

 
Intrinsic value

$8.13

 
Up/down potential

-41%

 
Rating

sell

 
Value-price divergence*

-150%

*Intrinsic value change (in %) minus stock price change (in %) in the past 12 months.

We calculate the intrinsic value of MDXG stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 2016), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.5

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
2016(a)
   2017
   2018
   2019
   2020
   2021
   2022
   2023
   2024
   2025
   2026
   2027
   2028
   2029
   2030
   2031
   2032
   2033
   2034
   2035
   2036
   2037
   2038
   2039
   2040
   2041
   2042
   2043
   2044
   2045
   2046

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  31.02
  33.30
  30.47
  27.92
  25.63
  23.57
  21.71
  20.04
  18.54
  17.18
  15.96
  14.87
  13.88
  12.99
  12.19
  11.47
  10.83
  10.24
  9.72
  9.25
  8.82
  8.44
  8.10
  7.79
  7.51
  7.26
  7.03
  6.83
  6.65
  6.48
  6.33
Revenue, $m
  245
  327
  426
  545
  685
  846
  1,030
  1,236
  1,465
  1,717
  1,991
  2,287
  2,605
  2,943
  3,302
  3,681
  4,080
  4,498
  4,935
  5,391
  5,867
  6,362
  6,877
  7,413
  7,969
  8,548
  9,149
  9,773
  10,423
  11,098
  11,801
Variable operating expenses, $m
 
  284
  371
  473
  594
  734
  893
  1,071
  1,269
  1,487
  1,724
  1,978
  2,253
  2,546
  2,856
  3,184
  3,528
  3,890
  4,268
  4,662
  5,074
  5,502
  5,948
  6,411
  6,892
  7,392
  7,912
  8,452
  9,014
  9,598
  10,206
Fixed operating expenses, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total operating expenses, $m
  227
  284
  371
  473
  594
  734
  893
  1,071
  1,269
  1,487
  1,724
  1,978
  2,253
  2,546
  2,856
  3,184
  3,528
  3,890
  4,268
  4,662
  5,074
  5,502
  5,948
  6,411
  6,892
  7,392
  7,912
  8,452
  9,014
  9,598
  10,206
Operating income, $m
  18
  42
  56
  72
  91
  112
  137
  165
  196
  230
  267
  309
  352
  398
  446
  498
  551
  608
  667
  729
  793
  860
  930
  1,002
  1,077
  1,155
  1,237
  1,321
  1,409
  1,500
  1,595
EBITDA, $m
  23
  49
  64
  81
  102
  126
  154
  185
  219
  257
  298
  342
  389
  440
  493
  550
  610
  672
  737
  806
  877
  951
  1,028
  1,108
  1,191
  1,277
  1,367
  1,460
  1,557
  1,658
  1,763
Interest expense (income), $m
  0
  0
  1
  2
  3
  4
  5
  7
  8
  10
  13
  15
  17
  20
  23
  26
  29
  33
  36
  40
  44
  48
  52
  57
  61
  66
  71
  76
  82
  87
  93
Earnings before tax, $m
  18
  42
  55
  70
  88
  109
  132
  158
  188
  220
  255
  294
  335
  378
  423
  471
  522
  575
  631
  689
  749
  812
  877
  945
  1,016
  1,089
  1,165
  1,245
  1,327
  1,413
  1,502
Tax expense, $m
  6
  11
  15
  19
  24
  29
  36
  43
  51
  59
  69
  79
  90
  102
  114
  127
  141
  155
  170
  186
  202
  219
  237
  255
  274
  294
  315
  336
  358
  381
  406
Net income, $m
  12
  31
  40
  51
  64
  79
  96
  116
  137
  160
  186
  215
  244
  276
  309
  344
  381
  420
  460
  503
  547
  593
  640
  690
  742
  795
  851
  909
  969
  1,031
  1,097

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  34
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  193
  212
  277
  354
  444
  549
  668
  802
  951
  1,114
  1,292
  1,484
  1,690
  1,910
  2,143
  2,389
  2,647
  2,919
  3,202
  3,498
  3,807
  4,128
  4,463
  4,810
  5,171
  5,547
  5,937
  6,342
  6,764
  7,202
  7,658
Adjusted assets (=assets-cash), $m
  159
  212
  277
  354
  444
  549
  668
  802
  951
  1,114
  1,292
  1,484
  1,690
  1,910
  2,143
  2,389
  2,647
  2,919
  3,202
  3,498
  3,807
  4,128
  4,463
  4,810
  5,171
  5,547
  5,937
  6,342
  6,764
  7,202
  7,658
Revenue / Adjusted assets
  1.541
  1.542
  1.538
  1.540
  1.543
  1.541
  1.542
  1.541
  1.540
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
  1.541
Average production assets, $m
  28
  37
  49
  62
  78
  96
  117
  141
  167
  196
  227
  261
  297
  336
  376
  420
  465
  513
  563
  615
  669
  725
  784
  845
  908
  974
  1,043
  1,114
  1,188
  1,265
  1,345
Working capital, $m
  76
  56
  73
  93
  117
  145
  176
  211
  251
  294
  341
  391
  445
  503
  565
  629
  698
  769
  844
  922
  1,003
  1,088
  1,176
  1,268
  1,363
  1,462
  1,564
  1,671
  1,782
  1,898
  2,018
Total debt, $m
  0
  20
  44
  73
  108
  147
  192
  242
  299
  360
  427
  500
  577
  660
  748
  841
  938
  1,040
  1,147
  1,259
  1,375
  1,496
  1,622
  1,753
  1,890
  2,031
  2,178
  2,331
  2,490
  2,655
  2,827
Total liabilities, $m
  60
  80
  104
  133
  168
  207
  252
  302
  359
  420
  487
  560
  637
  720
  808
  901
  998
  1,100
  1,207
  1,319
  1,435
  1,556
  1,682
  1,813
  1,950
  2,091
  2,238
  2,391
  2,550
  2,715
  2,887
Total equity, $m
  133
  132
  172
  220
  277
  342
  416
  500
  592
  694
  805
  925
  1,053
  1,190
  1,335
  1,488
  1,649
  1,818
  1,995
  2,180
  2,372
  2,572
  2,780
  2,997
  3,222
  3,456
  3,699
  3,951
  4,214
  4,487
  4,771
Total liabilities and equity, $m
  193
  212
  276
  353
  445
  549
  668
  802
  951
  1,114
  1,292
  1,485
  1,690
  1,910
  2,143
  2,389
  2,647
  2,918
  3,202
  3,499
  3,807
  4,128
  4,462
  4,810
  5,172
  5,547
  5,937
  6,342
  6,764
  7,202
  7,658
Debt-to-equity ratio
  0.000
  0.150
  0.260
  0.330
  0.390
  0.430
  0.460
  0.490
  0.500
  0.520
  0.530
  0.540
  0.550
  0.550
  0.560
  0.560
  0.570
  0.570
  0.580
  0.580
  0.580
  0.580
  0.580
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
  0.590
Adjusted equity ratio
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623
  0.623

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  12
  31
  40
  51
  64
  79
  96
  116
  137
  160
  186
  215
  244
  276
  309
  344
  381
  420
  460
  503
  547
  593
  640
  690
  742
  795
  851
  909
  969
  1,031
  1,097
Depreciation, amort., depletion, $m
  5
  7
  8
  10
  12
  14
  17
  20
  23
  26
  30
  33
  37
  42
  47
  52
  58
  64
  70
  77
  84
  91
  98
  106
  114
  122
  130
  139
  149
  158
  168
Funds from operations, $m
  15
  37
  48
  61
  76
  93
  113
  135
  160
  187
  216
  247
  281
  318
  356
  397
  439
  484
  531
  579
  630
  683
  738
  796
  855
  917
  981
  1,048
  1,117
  1,190
  1,265
Change in working capital, $m
  -11
  14
  17
  20
  24
  28
  31
  35
  39
  43
  47
  51
  54
  58
  61
  65
  68
  71
  75
  78
  81
  85
  88
  92
  95
  99
  103
  107
  111
  116
  120
Cash from operations, $m
  26
  23
  31
  41
  52
  66
  82
  100
  121
  144
  169
  197
  227
  260
  295
  332
  371
  412
  456
  501
  549
  599
  650
  704
  760
  818
  878
  941
  1,006
  1,074
  1,145
Maintenance CAPEX, $m
  0
  -4
  -5
  -6
  -8
  -10
  -12
  -15
  -18
  -21
  -24
  -28
  -33
  -37
  -42
  -47
  -52
  -58
  -64
  -70
  -77
  -84
  -91
  -98
  -106
  -114
  -122
  -130
  -139
  -149
  -158
New CAPEX, $m
  -6
  -9
  -11
  -14
  -16
  -18
  -21
  -24
  -26
  -29
  -31
  -34
  -36
  -39
  -41
  -43
  -45
  -48
  -50
  -52
  -54
  -56
  -59
  -61
  -63
  -66
  -69
  -71
  -74
  -77
  -80
Cash from investing activities, $m
  -12
  -13
  -16
  -20
  -24
  -28
  -33
  -39
  -44
  -50
  -55
  -62
  -69
  -76
  -83
  -90
  -97
  -106
  -114
  -122
  -131
  -140
  -150
  -159
  -169
  -180
  -191
  -201
  -213
  -226
  -238
Free cash flow, $m
  14
  11
  15
  21
  28
  38
  49
  62
  77
  94
  114
  135
  158
  184
  212
  242
  273
  307
  342
  379
  418
  459
  501
  545
  591
  639
  688
  740
  793
  849
  906
Issuance/(repayment) of debt, $m
  0
  20
  24
  29
  34
  39
  45
  50
  56
  62
  67
  72
  78
  83
  88
  93
  98
  102
  107
  112
  116
  121
  126
  131
  136
  141
  147
  153
  159
  165
  172
Issuance/(repurchase) of shares, $m
  -8
  2
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  -8
  22
  24
  29
  34
  39
  45
  50
  56
  62
  67
  72
  78
  83
  88
  93
  98
  102
  107
  112
  116
  121
  126
  131
  136
  141
  147
  153
  159
  165
  172
Total cash flow (excl. dividends), $m
  6
  33
  40
  50
  63
  77
  94
  112
  133
  156
  181
  207
  236
  267
  300
  334
  371
  409
  449
  491
  534
  580
  627
  676
  727
  780
  835
  892
  952
  1,014
  1,078
Retained Cash Flow (-), $m
  -25
  -33
  -40
  -48
  -56
  -65
  -74
  -83
  -93
  -102
  -111
  -120
  -128
  -137
  -145
  -153
  -161
  -169
  -177
  -184
  -192
  -200
  -208
  -216
  -225
  -234
  -243
  -253
  -263
  -273
  -284
Prev. year cash balance distribution, $m
 
  34
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
 
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
 
  34
  -1
  2
  6
  12
  19
  29
  40
  54
  70
  87
  108
  130
  155
  181
  210
  240
  272
  306
  342
  379
  419
  459
  502
  546
  592
  640
  689
  741
  794
Discount rate, %
 
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
 
  32
  -1
  2
  5
  9
  14
  19
  25
  31
  37
  41
  46
  49
  52
  53
  53
  52
  50
  47
  43
  39
  35
  30
  26
  21
  17
  14
  11
  8
  6
Current shareholders' claim on cash, %
  100
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8
  99.8

MiMedx Group, Inc. is an integrated developer, processor and marketer of regenerative biomaterial products and bioimplants human placental tissue, skin and bone. The Company's Regenerative Biomaterials segment includes the design, manufacture, and marketing of products and tissue processing services for the Wound Care, Surgical, Sports Medicine, Ophthalmic and Dental market categories. Its biomaterial platform technologies include AmnioFix, EpiFix, OrthoFlo, Physio, AlloBurn, and CollaFix. AmnioFix and EpiFix are its tissue technologies processed from human amniotic membrane derived from donated placentas. OrthoFlo is amniotic fluid-derived allograft for homologous use. Physio is a bone grafting material consists of bone tissue with no added carrier. CollaFix, its new brand, is its collagen fiber technology designed to mimic the natural composition, structure and mechanical properties of musculoskeletal tissues in order to augment their repair.

FINANCIAL RATIOS  of  MiMedx Group (MDXG)

Valuation Ratios
P/E Ratio 126.6
Price to Sales 6.2
Price to Book 11.4
Price to Tangible Book
Price to Cash Flow 58.4
Price to Free Cash Flow 76
Growth Rates
Sales Growth Rate 31%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 0%
Cap. Spend. - 3 Yr. Gr. Rate 24.6%
Financial Strength
Quick Ratio NaN
Current Ratio 0
LT Debt to Equity 0%
Total Debt to Equity 0%
Interest Coverage 0
Management Effectiveness
Return On Assets 7.3%
Ret/ On Assets - 3 Yr. Avg. 12.4%
Return On Total Capital 10%
Ret/ On T. Cap. - 3 Yr. Avg. 15.6%
Return On Equity 10%
Return On Equity - 3 Yr. Avg. 15.6%
Asset Turnover 1.5
Profitability Ratios
Gross Margin 86.9%
Gross Margin - 3 Yr. Avg. 88.7%
EBITDA Margin 9.4%
EBITDA Margin - 3 Yr. Avg. 10.5%
Operating Margin 7.3%
Oper. Margin - 3 Yr. Avg. 8.7%
Pre-Tax Margin 7.3%
Pre-Tax Margin - 3 Yr. Avg. 8.7%
Net Profit Margin 4.9%
Net Profit Margin - 3 Yr. Avg. 8.5%
Effective Tax Rate 33.3%
Eff/ Tax Rate - 3 Yr. Avg. 8.9%
Payout Ratio 0%

MDXG stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the MDXG stock intrinsic value calculation we used $245 million for the last fiscal year's total revenue generated by MiMedx Group. The default revenue input number comes from 2016 income statement of MiMedx Group. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our MDXG stock valuation model: a) initial revenue growth rate of 33.3% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for MDXG is calculated based on our internal credit rating of MiMedx Group, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of MiMedx Group.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of MDXG stock the variable cost ratio is equal to 87.3%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $0 million in the base year in the intrinsic value calculation for MDXG stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 3.5% for MiMedx Group.

Corporate tax rate of 27% is the nominal tax rate for MiMedx Group. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the MDXG stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for MDXG are equal to 11.4%.

Life of production assets of 8 years is the average useful life of capital assets used in MiMedx Group operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for MDXG is equal to 17.1%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $133 million for MiMedx Group - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 108.247 million for MiMedx Group is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of MiMedx Group at the current share price and the inputted number of shares is $1.5 billion.

RELATED COMPANIES Price Int.Val. Rating
SIEN Sientra 14.92 1.04  str.sell
IART Integra LifeSc 50.97 25.62  sell
ZBH Zimmer Biomet 121.88 45.88  str.sell
ALQA Alliqua BioMed 3.40 0.11  str.sell
CUTR Cutera 37.60 124.89  str.buy

COMPANY NEWS

▶ MiMedx Warns Of Fake Emails   [Oct-17-17 09:00AM  PR Newswire]
▶ IBD Rating Upgrades: MiMedx Flashes Improved Relative Price Strength   [Oct-05-17 03:00AM  Investor's Business Daily]
▶ MiMedx Files Lawsuit Related To Short Seller Attacks   [Oct-04-17 09:35AM  PR Newswire]
▶ Health care is the most complex business entity: MiMedx CEO   [Sep-26-17 12:26PM  Fox Business Videos]
▶ Stocks With Rising Relative Price Strength: MiMedx   [03:00AM  Investor's Business Daily]
▶ MiMedx Files Lawsuit Against The Capitol Forum   [Sep-21-17 09:41AM  PR Newswire]
▶ MiMedx Responds To Deceptive Short Seller Reports   [Sep-20-17 04:00PM  PR Newswire]
▶ MiMedx Patent Infringement Lawsuit Updates   [Sep-18-17 03:07PM  PR Newswire]
▶ Apple Bucks Market Drop, In Buy Zone; Will These 4 Breakouts Fly?   [Aug-23-17 01:58PM  Investor's Business Daily]
▶ Metro Atlanta's MiMedx to spin out subsidiary to focus on biopharma   [Aug-21-17 01:15PM  American City Business Journals]
▶ Three Stocks Breaking Out   [12:58PM  Benzinga]
▶ ETFs with exposure to MiMedx Group, Inc. : August 1, 2017   [Aug-01-17 04:54PM  Capital Cube]
▶ MiMedx posts 2Q profit   [01:00AM  Associated Press]
▶ /C O R R E C T I O N -- MiMedx Group, Inc./   [Jul-13-17 10:08PM  PR Newswire]
▶ ETFs with exposure to MiMedx Group, Inc. : July 11, 2017   [Jul-11-17 02:48PM  Capital Cube]
▶ ETFs with exposure to MiMedx Group, Inc. : June 30, 2017   [Jun-30-17 03:09PM  Capital Cube]
▶ ETFs with exposure to MiMedx Group, Inc. : June 19, 2017   [Jun-19-17 03:41PM  Capital Cube]
▶ Can This 2015 Medical IPO Inject New Life Into Its Stock?   [May-24-17 12:03PM  Investor's Business Daily]
▶ MiMedx EpiFix® Receives Coverage From Kaiser Permanente   [May-04-17 08:30AM  PR Newswire]
▶ Merger Buzz Drives Akorn to Top of Health Chart in April   [Apr-30-17 04:20PM  TheStreet.com]
▶ MiMedx beats 1Q profit forecasts   [07:28AM  Associated Press]
▶ 4 Stocks With Strong Technical Momentum   [Apr-21-17 08:40AM  Benzinga]
▶ ETFs with exposure to MiMedx Group, Inc. : April 17, 2017   [Apr-17-17 12:58PM  Capital Cube]
Financial statements of MDXG
Valuation of Stocks

The paper VALUATION OF STOCKS: The Quest for Intrinsic Value provides a detailed description of our valuation model and discloses the calculation algorithm.

FREE DOWNLOAD
Follow us on:   twitter   twitter   twitter   twitter

VALUATION THEORY       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2017. All rigths reserved.